Cardiac surgery in patients with liver cirrhosis: risk factors for predicting mortality

Cheng-Hsin Lin1, Ron-Bin Hsu1

  • 1Cheng-Hsin Lin, Ron-Bin Hsu, Department of Surgery, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei 100, Taiwan.

Insights

Cardiac surgery is feasible in cirrhotic patients, with preoperative serum bilirubin, EuroSCORE, and coronary artery bypass grafting (CABG) predicting mortality. Advanced liver cirrhosis should not prevent patients from undergoing necessary cardiac procedures.

Area of Science:

  • Cardiology
  • Hepatology
  • Surgical Outcomes

Background:

  • Cardiac surgery in patients with liver cirrhosis presents unique challenges due to altered physiology and increased risk of complications.
  • Assessing the safety and identifying predictors of mortality in this high-risk population is crucial for surgical decision-making.

Purpose of the Study:

  • To evaluate the outcomes of cardiac surgery in patients with liver cirrhosis.
  • To identify predictors of early and late mortality following cardiac surgery in cirrhotic patients.

Main Methods:

  • A cohort of 55 cirrhotic patients undergoing cardiac surgery between 1993 and 2012 was analyzed.
  • Child-Turcotte-Pugh (Child) classification and Model for End-Stage Liver Disease (MELD) score assessed liver disease severity.
  • Logistic regression and Cox proportional hazard models identified mortality predictors; survival analysis used Kaplan-Meier curves.

Main Results:

  • Hospital mortality was 16.4%; 1, 3, and 5-year actuarial survival rates were 70%, 56%, and 44%, respectively.
  • Preoperative serum bilirubin, EuroSCORE, and coronary artery bypass grafting (CABG) were associated with mortality.
  • Child class and MELD score did not independently predict mortality, contrary to expectations.

Conclusions:

  • Cardiac surgery can be safely performed in patients with advanced liver cirrhosis.
  • Preoperative serum bilirubin levels, the EuroSCORE, and the type of surgery (CABG) are significant predictors of mortality, guiding risk stratification.
Abstract

Related Concept Videos

Cardiomyopathy VII: Pre and Post Operative Nursing Management01:28

Cardiomyopathy VII: Pre and Post Operative Nursing Management

Patients with hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract (LVOT) obstruction who remain symptomatic despite optimal medical therapy may undergo a septal myectomy (Morrow procedure). This procedure involves excising a portion of the hypertrophied septum below the aortic valve using a heart-lung machine to improve blood flow through the LVOT. Effective preoperative and postoperative nursing management ensures successful patient outcomes, minimizes complications, and...
454
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
23
Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
872
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
377
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to...
26
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
271